For example, immune checkpoint therapy represented by PD-1 is applicable to fewer patients; CAR-T-cell immunotherapy modalities have cytokine storms and solid tumor effect defects; DNA tumor nucleic acid vaccines have poor immunogenicity and systemic immunotoxicity [11]. Here, PDCD1 is linked to neoplasm.